Market Overview:
ALK-TKIs are a type of targeted therapy that block the activity of an abnormal protein called ALK. This abnormal protein is found in some cancer cells. When the ALK-TKI blocks the activity of this protein, it may help to stop or slow the growth of cancer cells. The global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market is expected to grow at a CAGR of XX% and reach a value of USD XX million by 2030. The market is segmented on the basis of type, application and region. Regionally North America Latin America Europe Asia Pacific Middle East & Africa hold major shares in terms thereof due higher adoption rates for novel therapies coupled with increasing prevalence rates for various types if cancers where as developing economies such as Asia Pacific.
 Industry Outlook.svg)
Product Definition:
ALK-TKIs are a type of cancer drug that blocks the activity of the ALK protein tyrosine kinase. This enzyme is involved in the growth and spread of cancer cells, so blocking its activity can help to stop or slow down tumor growth.
Crizotinib:
Crizotinib is a drug that works by blocking the activity of ALK tyrosine kinase. The global market for ALK-TKIs has been growing at a rapid pace due to an increase in the number of patients suffering from Non-Small Cell Lung Cancer (NSCLC) and large scale adoption of second/third line treatment therapies.
Alectinib:
Alectinib is a novel oral inhibitor of the vascular endothelial growth factor (VEGF) and it's used in the treatment of patients with metastatic melanoma. The drug was approved by the FDA in March 2018 for treatment of patients with unresectable or metastatic melanoma who are intolerant to or have failed prior therapies including PD-1/PD-L1 inhibitors.
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to a high prevalence of cancer across various other organs, such as kidney, liver, and breast among others. Moreover, there are several drugs under this category that are in phase III or IV of clinical trials which include axitinib and Iressa (irinotecan) for lung cancer and solid tumor respectively.
However, leukemia is anticipated to be the fastest-growing application segment over the forecast period owing to an increase in incidence rates for different types including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B cell non-hodgkin¢â‚¬â„¢s lymphoma & small Lymph Node Disorders (N0/N1) coupled with an increasing number of deaths caused by these diseases worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of key manufacturers and a large number of clinical studies conducted on ALK-TKI drugs are some factors responsible for its dominance. Moreover, the high cost of these drugs is also one factor that has limited their use in this region. However, Asia Pacific is expected to be the fastest growing regional market during the forecast period owing to an increase in awareness levels regarding these diseases and rising healthcare expenditure by governments as well as individuals.
Moreover, Asian countries have a huge base of patients suffering from chronic diseases such as cancer and leukemia which will boost growth further due to an increase in awareness about early diagnosis leading to higher treatment rates resulting into higher revenue generation capacity for ALK-TKI inhibitors over there compared with other regions globally. Also, China has been observed purchasing large quantities of crizotinib from U.S., which indicates high unmet demand for crizotinib within China itself (Zhang et al., 2016).
Growth Factors:
- Increasing incidence of ALK-positive NSCLC: The incidence of ALK-positive non-small cell lung cancer (NSCLC) is increasing at a fast pace. This is mainly because of the improved detection techniques and increased awareness about the disease. This is expected to drive the demand for ALK-TKIs in the coming years.
- Growing popularity of targeted therapies: The growing popularity of targeted therapies is another major growth driver for the ALK-TKI market. Targeted therapies are specifically designed to treat a particular type or subtype of cancer, which makes them more effective than traditional chemotherapy regimens.
- Rising R&D investments by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D to develop novel drugs that can target different types of cancers, including those that are resistant to traditional treatments like chemotherapy and radiation therapy. This is likely to boost the demand for ALK inhibitors in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Research Report
By Type
Crizotinib, Alectinib, Ceritinib, Brigatinib, Lorlatinib, Ensartinib, CT-707
By Application
Leukemia, Solid Tumor, Lung Cancer, Others
By Companies
Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding, Chugai Pharmaceutical Co
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
142
Number of Tables & Figures
100
Customization Available
Yes, the report can be customized as per your need.
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Report Segments:
The global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market is segmented on the basis of:
Types
Crizotinib, Alectinib, Ceritinib, Brigatinib, Lorlatinib, Ensartinib, CT-707
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Leukemia, Solid Tumor, Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Nuvartis
- Takeda
- Betta Pharma
- Shouyao Holding
- Chugai Pharmaceutical Co
 Market Overview.svg)
Highlights of The ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Crizotinib
- Alectinib
- Ceritinib
- Brigatinib
- Lorlatinib
- Ensartinib
- CT-707
- By Application:
- Leukemia
- Solid Tumor
- Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ALK-TKIs are medications that block the activity of ALK tyrosine kinases. These drugs can be used to treat a variety of cancers, including leukemia and lymphoma.
Some of the major companies in the alk tyrosine kinase inhibitors (alk-tkis) market are Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding, Chugai Pharmaceutical Co.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size & Forecast, 2020-2028
4.5.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size and Y-o-Y Growth
4.5.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Crizotinib
5.2.2 Alectinib
5.2.3 Ceritinib
5.2.4 Brigatinib
5.2.5 Lorlatinib
5.2.6 Ensartinib
5.2.7 CT-707
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Leukemia
6.2.2 Solid Tumor
6.2.3 Lung Cancer
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Crizotinib
9.6.2 Alectinib
9.6.3 Ceritinib
9.6.4 Brigatinib
9.6.5 Lorlatinib
9.6.6 Ensartinib
9.6.7 CT-707
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Leukemia
9.10.2 Solid Tumor
9.10.3 Lung Cancer
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Crizotinib
10.6.2 Alectinib
10.6.3 Ceritinib
10.6.4 Brigatinib
10.6.5 Lorlatinib
10.6.6 Ensartinib
10.6.7 CT-707
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Leukemia
10.10.2 Solid Tumor
10.10.3 Lung Cancer
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Crizotinib
11.6.2 Alectinib
11.6.3 Ceritinib
11.6.4 Brigatinib
11.6.5 Lorlatinib
11.6.6 Ensartinib
11.6.7 CT-707
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Leukemia
11.10.2 Solid Tumor
11.10.3 Lung Cancer
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Crizotinib
12.6.2 Alectinib
12.6.3 Ceritinib
12.6.4 Brigatinib
12.6.5 Lorlatinib
12.6.6 Ensartinib
12.6.7 CT-707
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Leukemia
12.10.2 Solid Tumor
12.10.3 Lung Cancer
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Crizotinib
13.6.2 Alectinib
13.6.3 Ceritinib
13.6.4 Brigatinib
13.6.5 Lorlatinib
13.6.6 Ensartinib
13.6.7 CT-707
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Leukemia
13.10.2 Solid Tumor
13.10.3 Lung Cancer
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market: Competitive Dashboard
14.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Nuvartis
14.3.3 Takeda
14.3.4 Betta Pharma
14.3.5 Shouyao Holding
14.3.6 Chugai Pharmaceutical Co
